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Abstract
Background: In sporadic ovarian cancer, we have previously reported allele loss at D6S193 (62%)
on chromosome 6q27, which suggested the presence of a putative tumour suppressor gene. Based
on our data and that from another group, the minimal region of allele loss was between D6S264
and D6S149 (7.4 cM). To identify the putative tumour suppressor gene, we established a physical
map initially with YACs and subsequently with PACs/BACs from D6S264 to D6S149. To accelerate
the identification of genes, we sequenced the entire contig of approximately 1.1 Mb. Seven genes
were identified within the region of allele loss between D6S264 and D6S149.
Results: The human homologue of unc-93 (UNC93A) in C. elegans was identified to be within the
interval of allele loss centromeric to D6S149. This gene is 24.5 kb and comprises of 8 exons. There
are two transcripts with the shorter one due to splicing out of exon 4. It is expressed in testis,
small intestine, spleen, prostate, and ovary. In a panel of 8 ovarian cancer cell lines, UNC93A
expression was detected by RT-PCR which identified the two transcripts in 2/8 cell lines. The entire
coding sequence was examined for mutations in a panel of ovarian tumours and ovarian cancer cell
lines. Mutations were identified in exons 1, 3, 4, 5, 6 and 8. Only 3 mutations were identified
specifically in the tumour. These included a c.452G>A (W151X) mutation in exon 3, c.676C>T
(R226X) in exon 5 and c.1225G>A(V409I) mutation in exon 8. However, the mutations in exon 3
and 5 were also present in 6% and 2% of the normal population respectively. The UNC93A cDNA
was shown to express at the cell membrane and encodes for a protein of 60 kDa.
Conclusions: These results suggest that no evidence for UNC93A as a tumour suppressor gene
in sporadic ovarian cancer has been identified and further research is required to evaluate its
normal function and role in the pathogenesis of ovarian cancer.
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Background
Ovarian cancer is the most frequent cause of death from
gynaecological malignancies in the Western World [1].
Epithelial ovarian cancer constitutes 70–80% of ovarian
cancer and encompasses a broad spectrum of lesions,
ranging from localised benign tumours and neoplasms of
borderline malignant potential to invasive adenocarcino-
mas. The p53 gene has been found to be frequently mu-
tated (50%) in sporadic malignant ovarian tumours [2].
The BRCA1 and BRCA2 genes are mutated in a proportion
of patients with familial breast/ovarian cancer [3]. How-
ever, familial ovarian cancer accounts only for 5–10% of
all ovarian tumours [4]. In tumours from patients with
sporadic ovarian cancer, only five mutations in the BRCA1
gene and four in the BRCA2 gene have been reported sug-
gesting that they are rare in sporadic ovarian cancer [5,6].
However, epigenetic inactivation due to methylation has
been reported for BRCA1 and 2 in a proportion of sporad-
ic tumours [7]. Mutations in the mismatch repair genes
have been reported at a frequency of 10% in sporadic
ovarian cancer [8]. More recently, the PTEN gene has been
reported to be mutated in 20% of endometrioid subtype
of sporadic ovarian tumours [9]. However, detailed evalu-
ation by mutation analysis and immunohistochemistry
has shown inactivation of PTEN in other subtypes of ovar-
ian cancer [10]. Thus tumour suppressor genes that may
be more critical in tumour progression in sporadic ovari-
an cancer have not yet been fully characterised [11].
Chromosome 6 has been implicated to contain a putative
tumour suppressor gene important in the pathogenesis of
ovarian cancer, both by karyotypic analysis and allele loss
studies. The analysis of 70 malignant ovarian tumours us-
ing cosmids mapping to chromosomal arm 6q initially
defined the minimal region of allele loss between D6S149
and D6S193 (1.9 cM) in one tumour [12,13]. Subsequent
studies have shown increased frequency of allele loss on
6q around the same region, although a minimal region
was not defined [14,15]. Based on the analysis of 56 ma-
lignant ovarian tumours we showed previously that the
minimal region of allele loss on 6q27 is between D6S297
and D6S264 (3 cM) (Figure 1). The maximal frequency of
Figure 1
Genomic structure and ESTs corresponding to UNC93A. PAC 366N23 contains the entire gene for UNC93A and
exons 8 and 9 of TCP10. The individual exons of UNC93A are shown diagrammatically. The alternative splice variant is with-
out exon 4. Individual ESTs (accession numbers) are shown based on their sequence homology to UNC93A cDNA.
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allele loss occurred at D6S193 (62%) and D6S297 (52%)
which are approximately 55 Kb apart. Three tumours
showed loss of D6S193 only, while retaining flanking
markers thus suggesting that the putative tumour suppres-
sor gene was close to D6S193. The allele loss was observed
in all types of epithelial ovarian cancer [16–18]. Further
evidence that there might be a putative tumour suppressor
gene around D6S193 is provided by FISH studies using
YACs on direct metaphase spreads from fresh ovarian tu-
mours which suggested that this change might be impor-
tant even in early ovarian tumours [19,20]. More recently,
a homozygous deletion has been mapped centromeric to
D6S193 in one ovarian cancer cell line [21]. Further, it is
possible that the same region is implicated in a subset of
lymphomas and breast cancer [22–26].
To identify the potential tumour suppressor gene on chro-
mosomal band 6q27 implicated in the pathogenesis of
ovarian cancer, we undertook a positional cloning ap-
proach. We have constructed an extended bacterial clone
contig in PACs/BACs from D6S264 until D6S149 which
encompasses the maximal possible region of allele loss
from our data and that previously reported [12,16]. Sub-
sequently, we undertook sequencing of BACs/PACs which
mapped to the key polymorphic markers D6S193 and
D6S297 and we now have almost complete sequence of
the extended contig [27]. Seven genes were identified
within the interval between D6S264 and D6S149. This pa-
per reports the identification of the human homologue of
unc-93 in c. elegans [28] in the minimal region of allele
loss and its analysis in ovarian tumours.
Results
Physical mapping, genomic structure and cDNA sequence 
of UNC93A
Using the previously defined integrated genetic map of
chromosome 6q24-27 [17], we constructed an extended
bacterial clone contig (PACs/BACs) between D6S264 and
D6S149 [27]. To accelerate the identification of genes in
this region, we chose to sequence the entire region. We
now have contiguous sequence of approximately 1.1 Mb
between D6S264 and PAC RP11-178P20. The sequence is
incomplete between RP11-178P20 and RP3-431P23 that
contains D6S149. We identified seven genes in this region
by a variety of strategies. UNC93A and the last two exons
of TCP10 were identified by analysis of the sequence from
RP3-366N23 with a suite of exon prediction programmes.
Several ESTs were also mapped to the same genomic re-
gion (RP3-366N23) that was identified to contain the pre-
dicted gene (Fig. 1.) The gene for UNC93A is 24.5 kb in
length and comprises 8 exons. All the intron exon bound-
aries of UNC93A follow the GT/AG rule (Table 1).
The predicted cDNA of UNC93A was 1451 bp. Sequence
analysis of the individual ESTs confirmed that the full
length cDNA was slightly longer due to 3' untranslated se-
quence (2011 bp) (Fig. 2). The putative initiation methio-
nine was preceded by an inframe stop codon and had the
best Kozak's consensus sequence. The primary structure of
the protein predicts a leader peptide (1–25 aa) followed
by seven transmembrane domains. The size of the predict-
ed protein is 50 kDa. The amino acid sequence of
UNC93A is 30% homologous to the unc-93 sequence in
C.elegans (Fig. 3). There is another predicted homologous
protein in C.elegans (acc.no.Q93380) and two homolo-
gous predicted proteins in Drosophila (acc.no. Q9Y115
and Q9V4S6). The overall similarity in primary sequence,
particularly over the predicted transmembrane regions, is
highlighted.
As UNC93A mapped within the minimal region of allele
loss, it was potentially an attractive candidate as a tumour
suppressor gene. We analysed this gene in detail to try to
understand its expression in normal cells and its possible
involvement in the tumourigenesis of sporadic ovarian
cancer.
Table 1: Intron-exon structure of UNC93A.
EXON EXON SIZE (bp) INTRON SIZE (bp) 5' SPLICE SITE * 3' SPLICE SITE *
1 164 2941 gattgttttt/CCCATGCCTC GAGCCTGCAG/gtatgtgtt
2 181 1334 gttcccacag/AGCAGCCTGT TCGCCAGCTG/gtacgcagcc
3 229 1684 ttacccacag/GTACACTTTG CCCAGCCAAG/gtaaaaggaa
4 125 5613 gacttcatag/AGACCCTTCC ATCTACACTG/gtacgagctc
5 214 1768 gtcctttcag/GGAGTGGTGT ATACACAAGG/gtatgaacga
6 135 1729 ctctccccag/TCCTATGTCA TACGTGCTGG/gtaggtatca
7 131 7277 gcacccccag/GCGCGGTGAC CAAAACAATG/gtgagtcccc
8 827 tcctctgcag/CTCTCTACGG AAAAATGTGA/gagcagtgag
* Letters in lower case correspond to intron sequence and the upper case to exon sequence.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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Expression
None of the EST clones contained the full length UNC93A
cDNA upon sequencing. To isolate full length cDNA
clones and also to confirm the sequence of the predicted
cDNA, primers were designed to amplify the coding se-
quences of UNC93A. RT-PCR was performed using total
RNAs from normal ovary (epithelial cells) and the panel
of 8 ovarian cancer cell lines as templates. Two products
of 1.4 and 1.3 kb were observed in cell lines 41M and
OAW28 (Fig. 4A). Direct sequencing of these two prod-
ucts have shown that the 1.4 kb amplicon represented the
entire coding sequence of UNC93A and the 1.3 kb ampli-
con did not have exon 4. Another set of RT-PCR was car-
ried out to confirm the above result by using the same
panel of RNAs as templates with primers designed to am-
plify exon 3–5 (Fig. 4B). Again, two major amplicons were
observed in cell lines 41M and OAW28. Sequencing of
both PCR products showed that the smaller product did
not contain exon 4. Therefore, there are two splice variants
of UNC93A, with one containing all of the 8 exons and
one missing exon 4.
The UNC93A cDNA (1.4 kb) containing the entire open
reading frame was used as a probe in Northern analysis.
Hybridisation of UNC93A against a Northern blot of mul-
tiple human tissues, revealed a major transcript of about
Figure 2
cDNA and amino acid sequence of UNC93A. The entire cDNA of UNC93A is shown with the predicted peptide
sequence. Primary structure analysis of the protein has indicated that there is a leader peptide (boxed red) and seven trans-
membrane domains (boxed blue). The above prediction was obtained by the analysis of the protein by several structure predic-
tion programmes including SignalIP prediction, TMPred, TMHMM, TopPred, PredictProtein, and HMMTOP.
                 10                  30                  50                  70                  90                 110
                  .         .         .         .         .         .         .         .         .         .         .         .
      1  CCCATGCCTCAATTGGTTTCTTTTAGGGAGCTACAAATTTACGTGTTCACTGGTGATTGATCTTTTCATCCAGCACAATGGACAGAAGTCTAAGGAACGTCCTTGTGGTTTCCTTTGGGT   120
      1                                                                               M  D  R  S  L  R  N  V  L  V  V  S  F  G  F   15
                130                 150                 170                 190                 210                 230
                  .         .         .         .         .         .         .         .         .         .         .         .
    121  TCCTGCTTCTCTTTACAGCCTATGGAGGTCTGCAGAGCCTGCAGAGCAGCCTGTACAGCGAGGAGGGCCTGGGTGTCACAGCGCTCAGCACCCTCTATGGAGGCATGCTCCTGTCCTCCA   240
     16    L  L  L  F  T  A  Y  G  G  L  Q  S  L  Q  S  S  L  Y  S  E  E  G  L  G  V  T  A  L  S  T  L  Y  G  G  M  L  L  S  S  M   55
                250                 270                 290                 310                 330                 350
                  .         .         .         .         .         .         .         .         .         .         .         .
    241  TGTTCCTCCCACCGCTCCTCATCGAGAGGCTGGGCTGCAAGGGGACCATCATCCTCTCCATGTGTGGCTACGTGGCCTTCTCCGTGGGCAACTTCTTCGCCAGCTGGTACACTTTGATCC   360
     56    F  L  P  P  L  L  I  E  R  L  G  C  K  G  T  I  I  L  S  M  C  G  Y  V  A  F  S  V  G  N  F  F  A  S  W  Y  T  L  I  P   95
                370                 390                 410                 430                 450                 470
                  .         .         .         .         .         .         .         .         .         .         .         .
    361  CCACCTCCATACTGCTGGGACTCGGGGCCGCCCCGCTGTGGTCTGCACAGTGCACATACCTCACGATCACGGGAAACACACATGCAGAGAAGGCGGGAAAGCGTGGCAAAGACATGGTGA   480
     96    T  S  I  L  L  G  L  G  A  A  P  L  W  S  A  Q  C  T  Y  L  T  I  T  G  N  T  H  A  E  K  A  G  K  R  G  K  D  M  V  N   135
                490                 510                 530                 550                 570                 590
                  .         .         .         .         .         .         .         .         .         .         .         .
    481  ACCAGTATTTTGGCATCTTCTTCCTCATATTCCAGTCATCCGGTGTGTGGGGCAACTTGATCTCATCGCTGGTATTTGGCCAGACTCCCAGCCAAGAGACCCTTCCAGAAGAGCAGCTCA   600
    136    Q  Y  F  G  I  F  F  L  I  F  Q  S  S  G  V  W  G  N  L  I  S  S  L  V  F  G  Q  T  P  S  Q  E  T  L  P  E  E  Q  L  T   175
                610                 630                 650                 670                 690                 710
                  .         .         .         .         .         .         .         .         .         .         .         .
    601  CGTCCTGTGGGGCCAGTGACTGCCTGATGGCCACCACAACCACCAACAGCACCCAGAGGCCCTCCCAGCAGCTGGTCTACACCCTCCTGGGCATCTACACTGGGAGTGGTGTCCTGGCTG   720
    176    S  C  G  A  S  D  C  L  M  A  T  T  T  T  N  S  T  Q  R  P  S  Q  Q  L  V  Y  T  L  L  G  I  Y  T  G  S  G  V  L  A  V   215
                730                 750                 770                 790                 810                 830
                  .         .         .         .         .         .         .         .         .         .         .         .
    721  TCCTGATGATAGCTGCGTTCCTCCAACCCATACGAGATGTTCAGCGGGAAAGTGAAGGAGAGAAGAAATCAGTACCTTTCTGGTCCACTTTACTGTCGACTTTCAAGCTATATAGAGATA   840
    216    L  M  I  A  A  F  L  Q  P  I  R  D  V  Q  R  E  S  E  G  E  K  K  S  V  P  F  W  S  T  L  L  S  T  F  K  L  Y  R  D  K   255
                850                 870                 890                 910                 930                 950
                  .         .         .         .         .         .         .         .         .         .         .         .
    841  AACGTCTGTGCCTCTTAATTCTGCTGCCGCTGTACAGTGGATTGCAGCAAGGATTCCTCTCCAGCGAATACACAAGGTCCTATGTCACCTGCACCCTGGGCATCCAGTTCGTCGGCTACG   960
    256    R  L  C  L  L  I  L  L  P  L  Y  S  G  L  Q  Q  G  F  L  S  S  E  Y  T  R  S  Y  V  T  C  T  L  G  I  Q  F  V  G  Y  V   295
                970                 990                1010                1030                1050                1070
                  .         .         .         .         .         .         .         .         .         .         .         .
    961  TGATGATCTGCTTCTCGGCCACTGACGCGCTGTGCTCCGTGTTGTATGGAAAGGTCTCGCAGTACACGGGCAGGGCTGTGCTGTACGTGCTGGGCGCGGTGACCCACGTGTCCTGCATGA   1080
    296    M  I  C  F  S  A  T  D  A  L  C  S  V  L  Y  G  K  V  S  Q  Y  T  G  R  A  V  L  Y  V  L  G  A  V  T  H  V  S  C  M  I   335
               1090                1110                1130                1150                1170                1190
                  .         .         .         .         .         .         .         .         .         .         .         .
   1081  TTGCCCTACTGCTGTGGAGACCTCGTGCTGACCATCTGGCAGTGTTCTTCGTATTCTCTGGCCTGTGGGGCGTGGCAGATGCCGTCTGGCAGACACAAAACAATGCTCTCTACGGCGTTC   1200
    336    A  L  L  L  W  R  P  R  A  D  H  L  A  V  F  F  V  F  S  G  L  W  G  V  A  D  A  V  W  Q  T  Q  N  N  A  L  Y  G  V  L   375
               1210                1230                1250                1270                1290                1310
                  .         .         .         .         .         .         .         .         .         .         .         .
   1201  TGTTTGAGAAGAGCAAGGAAGCTGCCTTCGCCAATTACCGCCTGTGGGAGGCCCTGGGCTTCGTCATTGCCTTCGGGTACAGCATGTTTTTGTGCGTGCACGTCAAGCTCTACATTCTGC   1320
    376    F  E  K  S  K  E  A  A  F  A  N  Y  R  L  W  E  A  L  G  F  V  I  A  F  G  Y  S  M  F  L  C  V  H  V  K  L  Y  I  L  L   415
               1330                1350                1370                1390                1410                1430
                  .         .         .         .         .         .         .         .         .         .         .         .
   1321  TGGGGGTCCTGAGCCTGACCATGGTGGCGTATGGGCTTGTGGAGTGCGTGGAGTCCAAGAACCCGATCAGACCCCACGCTCCAGGACAGGTCAACCAGGCAGAGGATGAAGAAATACAAA   1440
    416    G  V  L  S  L  T  M  V  A  Y  G  L  V  E  C  V  E  S  K  N  P  I  R  P  H  A  P  G  Q  V  N  Q  A  E  D  E  E  I  Q  T   455
               1450                1470                1490                1510                1530                1550
                  .         .         .         .         .         .         .         .         .         .         .         .
   1441  CAAAAATGTGAGAGCAGTGAGGTCCGAGGAGGATGAACTCAGAAAGCACCAGCCAGAGAATTTTCTTAGAAGATGCCTCAGGACATAGAGCGGCTCCTCATCACCATCTCAGCACAATTT   1560
    456    K  M  *                                                                                                                   457
               1570                1590                1610                1630                1650                1670
                  .         .         .         .         .         .         .         .         .         .         .         .
   1561  GGCCATTCTGAAGAGATCATGTTATTTCACTCTTCATGTATTTTTTTCTATTCTAACAAATTTTTCGTCCACCATCTTAACAGAGATCAAGTGTATACATGAAGGTATCAGTTCATTTAA   1680
               1690                1710                1730                1750                1770                1790
                  .         .         .         .         .         .         .         .         .         .         .         .
   1681  TTTTAGATGCAAAAGAAAAAGGTCTAACGTACAATCAGCCAATTAGAATTTGCCTGAAATCATAGACTCACCCTAGTTTTATTGCTGTAGTTGTTTTTAAGAATTGGAAGCCTGCTTAAA   1800
               1810                1830                1850                1870                1890                1910
                  .         .         .         .         .         .         .         .         .         .         .         .
   1801  AAATGTAGTTGAGCCCCATAATTTTACAAATGGGCGAACTTTTAAACTTCTAACTCTACTTGGATCAAAACCTCATACATTTTACAAAGGGGTCCTGACAAGTCAGCTGACTCAACCTCA   1920
               1930                1950                1970                1990                2010
                  .         .         .         .         .         .         .         .         .
   1921  CAGAGTCAGGGGGTGACAAAGCCAGACTGGGGCTCAGGATTCCTGAAACGTGTGGGGTCTGCGTTTCTAAATAAAGACGGTTATTTAATGG  2011
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Figure 3
Alignment of UNC93A across species. Q23024 is the original unc-93 sequence in C. elegans. Q93380 is a predicted sec-
ond unc-93 like protein in C.elegans. Q9Y115 and Q9Y4S6 are two predicted proteins in Drosophila. Residues shaded red are
identical and in yellow are similar. The alignment was performed using Pileup (Blosum 62) and displayed using ESPRipt.
BBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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Figure 4
A) The expression of UNC93A in ovarian cancer cell lines by RT-PCR. Top panel: Ethidium-bromide stained agarose
gel of amplification products from the RT-PCR using primers located in exon 1 and exon 8 of the cDNA of UNC93A to amplify
the entire coding sequence. The template for the RT-PCR were the total RNAs from indicated ovarian cancer cell lines (2 g
each). Two products of 1.4 kb and 1.3 kb were observed in 41M and OAW28. Bottom panel: GAPDH was amplified by RT-
PCR using the same panel of RNAs as those used in the RT-PCR of the top panel. B) Amplification of exon 3–5 by RT-
PCR. Top panel: Ethidium-bromide stained agarose gel of amplification products from the RT-PCR using primers located in
exon 3 and exon 5 of the cDNA of UNC93A. The template of the RT-PCRs were the total RNAs from normal ovary tissue,
normal placenta tissue and 8 ovarian cancer cell lines (2 g each). A major RT-PCR amplicon about 550 bp was observed in all
the samples except in the negative control. Another amplicon about 400 bp was observed in cell lines 41M, OAW28. Bottom
panel: GAPDH was amplified by RT-PCR using the same panel of RNAs as those used in the RT-PCR of the top panel. C)
Northern blot analysis of the UNC93A expression in adult tissues. A Northern blot of poly (A)+ mRNA (2 g each
lane) from 8 adult tissues (Clontech) was hybridised to full length cDNA of UNC93A. The membrane was exposed to Fuji film
at -70C for 5 days. Two major transcripts of 1.1 and 2.2 kb were observed in spleen, prostate, testis, ovary, small intestine,
and colon.
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2.1 kb in testis, small intestine and colon; a smaller tran-
script of 1.1 kb was also observed in spleen, prostate, ova-
ry, small intestine, and colon (Fig. 4C). Using the same
probe to hybridise the Northern blot of 8 ovarian cancer
cell lines, no expression of this gene could be detected
(data not shown).
The entire coding sequence of UNC93A (nucleotide 78–
1448, Fig. 2A) was cloned in frame into pEGFP-N3 with
the GFP protein at the C-terminal end of UNC93A. Tran-
sient expression of this construct in 293-T cells, showed
clear membrane localisation of the fusion protein (Fig.
5A,5B,5C). In addition, immunoprecipitation of the GFP-
UNC93A fusion protein from the transfected cells, identi-
fied a specific band of 90 kDa (Fig. 5D). Thus, in vivo, the
UNC93A protein is approximately 60 kDa in size which is
slightly larger than that predicted from the amino-acid se-
quence. The increase from the predicted size could be due
to post-translational modifications.
Mutation analysis
We analysed the entire coding sequence of UNC93A for
mutations using initially SSCP (32P), then SSCP with flu-
orescent labelled oligonucleotide primers using an ABI
377 machine (F-SSCP) and then DHPLC in a panel of 36
malignant ovarian tumours. We have also sequenced the
entire cDNA in 8 ovarian cancer cell lines to detect muta-
tions.
Mutation detection using 32P-SSCP and F-SSCP
Primers were designed to amplify each exon of the
UNC93A gene (Table 2). Two sets of primers were de-
signed to amplify exon 8 with the PCR products (smaller
than 200 bp) overlapping each other (Table 2). Ten ma-
lignant ovarian tumours with allele loss of the key marker
D6S193 [16] were selected initially for 32P SSCP analysis
of all of the 8 exons of UNC93A. Variant bands were de-
tected in T68 in exon 3, T39 in exon 4 (Fig. 6A). Interest-
ingly, the variant bands detected in the tumours were also
present in the matched normal control for each tumour
compared to the placental DNA.
Subsequently, 36 malignant tumours (including the pre-
vious 10 samples) were analysed by F-SSCP in all 8 exons
of UNC93A. PCR samples were run on an ABI 377 Se-
quencer with the corresponding SSCP settings. Abnormal
peaks, which represented the variant bands in this study,
were observed in 5 tumours (T32, T60, T50, T30, T68) in
exon 3, in 4 tumours (T28, T34, T25, T39) in exon 4 and
in 5 tumours in exon 8 (T19, T34, T44, T49, T54) (Fig. 6B)
compared to normal control.
Mutation detection using DHPLC
To employ a mutation detection technique which would
not be affected by PCR product size, we used the DHPLC
(Denaturing High-Performance Liquid Chromatography)
method on a Transgenomic – WAVE machine to further
screen for mutations on the same panel of tumour sam-
ples. We also used DHPLC to evaluate exons in tumours
which were normal by the previous methods.
A new set of primers was designed to amplify the whole of
exon 8 to confirm the SSCP results for exon 8. In total, ex-
ons 1, 2, 5, 8 from the 36 tumour samples were amplified
by primers flanking the exons using the "touchdown" pro-
gramme [29] and subjected to the analysis on the WAVE
machine. The results from this study showed that there
were additional abnormal peaks in 6 tumours (T26, T29,
T32, T36, T37, and T59) in exon 1, and in one tumour
(T43) in exon 5 (Fig. 6C).
Mutations in UNC93A
Ovarian Tumours
In exon 3, 5 tumours were identified with abnormal SSCP
patterns (Table 3, Fig. 6A, 6B). Direct sequencing of the
exons showed that all of them had an identical single base
change c.452G>A that would alter amino-acid Trp to a
stop codon thereby truncating the protein. For 4 of these
tumours (T32, T68, T60 and T50), an identical alteration
was found in matched normal control DNA, suggesting
that this was not tumour specific. In tumour sample T30,
however, there was a heterozygous alteration c.452G>A at
this base which was not observed in the matched normal
DNA (Fig, 7A).
In exon 4, there were two tumours (T39 and T28) which
showed an abnormal SSCP pattern (Table 3, Fig. 6A,6B).
In both tumours, the abnormal variant in exon 4 was also
present in the matched normal DNA (Fig. 6A). Direct se-
quencing of this exon in both tumours revealed that there
was a splice site mutation at the first base in the intron at
the 3' end of the exon (c.625+1G>C). This mutation was
also present in the normal matched DNA (Fig. 7B). Direct
sequencing of the variant band in T39 (Fig. 6A) confirmed
this alteration.
In exon 5, one tumour (T43) had an abnormal pattern on
DHPLC (Fig. 7C). Direct sequencing of this exon revealed
that this was due to a mutation c.676C>T which would al-
ter amino acid Arg to a stop codon, thereby truncating the
protein. This mutation was tumour specific as it was not
present in the matched normal DNA (Fig. 7C).
In exon 8, there were abnormal patterns detected by SSCP
or DHPLC in 5 tumours (Fig. 6B, Table 4). All sequence
variants were present in the matched normal control DNA
(Fig. 8A,8B,8D) except one mutation in T19 where a sin-
gle base change c.1225G>A altered Val to Ile which is a
conservative alteration (Fig. 8C).BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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In exon 1, there were 6 tumours (T26, T29, T32, T36, T37
and T59) which showed an abnormal pattern on DHPLC
(Fig. 6C). Direct sequencing of this exon in all of the 6 tu-
mours identified a single base change 32 bp upstream of
the ATG in the 5' untranslated sequence of UNC93A (c.1-
32T>G). Sequencing of exon 1 from matched control nor-
mal DNA for all of these tumours showed an identical al-
teration (data not shown).
Ovarian cell lines
Direct sequencing of all of the exons of UNC93A was per-
formed in eight ovarian cancer cell lines (Table 5). In exon
1, 6/8 cell lines had the same mutation observed in tu-
Figure 5
In vivo expression of UNC93A. Cellular expression and localisation of GFP-UNC93A. The ORF of UNC93A was
subcloned inframe into a fluorescent GFP tagged mammalian expression vector (EGFP-N3) and was transiently transfected into
293-T cells. 24 hours after the transfection, the cells were transferred to cover slips for a further 24-hour culture, followed by
fixation and observed under fluorescent microscope. The fusion protein was localised on the membrane of the transfected
cells and was abundant from 48 to 72 hours after the transfection. A) cells observed under phase contrast, B) cells observed
under UV light, C) merged image. D) Immunoprecipitation and immunoblotting of the EGFP-UNC93A fusion pro-
tein. Cell lysate from untransfected 293-T cells, 293-T cells transfected with EGFP vector, and 293-T cells transfected with
EGFP-UNC93A (the EGFP + UNC93A lane) were immunoprecipitaed with GFP monoclonal antibody, resolved on an 10%
SDS-PAGE gel, and Western blotted. A specific fusion protein of about 90 kDa was detected with GFP monoclonal antibody
and anti-Mouse HRP in the cells transfected with EGFP-UNC93A, but not in the untransfected cells nor cells transfected with
EGFP vector (indicated by arrow).
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mours in the 5' untranslated sequence, c.1-32T>G. An
identical stop codon mutation in exon 3, c.452G>A, as
observed in tumours was detected in cell lines PEO1,
PEO4, OAW42, and SKOV3. The alteration was hetero-
zygous in two cell lines (OAW42, SKOV3) and ho-
mozygous in two (PEO1 and PEO4). A missense
mutation in exon 5, c.659C>T was observed in UCI101
which would confer a change of Ala to Val. A missense
mutation in exon 6, c.874G>A was observed in 6/8 cell
lines. This mutation would alter amino acid residue Val to
Ile, which is a conservative alteration. The mutations ob-
served in exons 5 and 6 in these cell lines were not ob-
served in tumours. In exon 8, identical in them alterations
as that observed in tumours were also identified (Table 5).
Normal population
As the mutation in exon 3 (c.452G>A), which creates a
stop codon, was present in one of the two alleles in several
matched normal samples, it was possible that this variant
was a polymorphism. We analysed exon 3 by F-SSCP in a
panel of 50 normal DNA samples (Caucasian). 3 samples
showed a different pattern on SSCP compared to placenta
(Fig. 9A). Direct sequencing of exon 3 from these 3 nor-
mal DNA samples, revealed that two were heterozygous
for the mutation c.452G>A and one was homozygous (Fig
9B). Similarly, the frequency of the mutation in exon 5,
c.676C>T, which creates a stop codon, in the normal pop-
ulation was also evaluated. This mutation creates a new
restriction site for the enzyme Nde1 (CATATG). There-
Figure 6
Mutation detection of UNC93A in ovarian tumors. A) Mutation detection using P32-SSCP method. Each exon
was amplified with DNAs from tumour sample, its matched control and normal placenta tissue. The variant bands in exon 3
and 4 in the tumour samples and their matched normals compared with normal placenta tissue are indicated by arrows. B)
Mutation detection using F-SSCP method. Representative examples are shown for exons 3, 4, and 8. The primers were
labelled with fluorescent dye (the forward primers were labelled with HEX, the reverse primers were labelled with FAM). The
electrograms are a graphical display of the fluorescent intensity on the y-axis and the mobility along the x-axis. The red peaks
are the GeneScan 500 size standard (Perkin Elmer) labelled with TAMRA, which functions as an internal control for each lane.
Placenta DNA was used as a normal control. The abnormal peaks in the tumours are indicated by arrows. C) Mutation
detection using DHPLC method. PCR was performed using primers flanking exons by 'touchdown' PCR and subjected to
DHPLC analysis. The electrograms are a graphical display of the amount of DNA run through the column (intensity peak) on
the y-axis and the retention time of the DNA in the column (minute) along the x-axis. The abnormal peaks in exon1 (T59) and
exon 5 (T43) are indicated by arrows. PCR products from placenta DNA was used as control.
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Figure 7
DNA sequence traces of the mutations detected in exon 3, 4, and 5 of UNC93A. A) Sequence trace of the nucle-
otide variant c.452G>A in exon3, which confers a stop codon, in tumor T30 compared with its matched normal DNA. B)
Sequence trace of the nucleotide variant c.625+1G>C at the 3' splice site of exon 4 in tumor T39, its matched normal and the
variant band from the P32-SSCP gel. C) Sequence trace of the nucleotide variant c.676C>T in exon 5, which confers a stop
codon, in tumor T43 and its matched normal. Corresponding amino acids are shown at the top of each sequence trace.
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fore, this exon was amplified by PCR from 50 normal
DNA samples and the PCR products were digested with
Nde1. One sample (ORK29) had an altered restriction
pattern suggestive of a heterozygous mutation (Fig. 10).
This was confirmed by direct sequencing of exon 5 in this
sample.
Discussion
The region between D6S264 and D6S149 is now well
mapped except for a gap between RP11-178P20 and RP3-
431P23. The latter PAC contains the telomeric marker
D6S149. The entire region has been sequenced (1.1 Mb)
and we have identified 7 genes [27]. One of the candidate
genes identified within this interval was the human
homologue of unc-93 in C.elegans. We chose to analyse
this gene in detail as it was expressed in the ovary and
Table 2: Primers for amplification of UNC93A genomic DNA.
EXON PRIMER 
NAME
PRIMER SEQUENCE (5'-3') PCR PRODUCT 
SIZE (BP)
ANNEALING TEMPERA-
TURE AND MG++ IN DHPLC 
DENATURING 
TEMPERATURE 
(C)
IN DHPLC GRA-
DIENT START 
(INITIAL Buffer 
B%)
1 1f GAATGGGACTTCTTGGTACTGATTG 225 61 C, 1 mM 59 52
1r TTCAGGTAATTTGATGACCGGACACA
2 2f CTGTGCTCTGACAGGGCTGGCTTTGT 244 62 C, 1.5 mM 65 52
2r GGGTGGGCAGGGGGTGGTGGCTGCT
3 3f CTATGGGTCTGCATTTTACCC 282 61 C, 1.5 mM 61 54
3r ACAATTGCTTGCCCCTTTTCCTTT
4 4f ATTTGCCGTCATCTCATGTCT 195 61 C, 2 mM - -
4r CTGCCCTGGGCCGATGGAGCTCGT
5 5f TGAAAGCTGAAGCCTTTGCTATGT 276 61 C, 1.5 mM 60 55
5r GAGCCACCGGCCCTCACTTTCGTT
6 6f GCCTGGGAGCGTCCATGACGTGGC 204 61 C, 1.5 mM - -
6r GGATGGGACCCACGCTGATACCTA
7 7f TCCCCTCTGCACCCCCAGGCGCGG 167 61 C, 2 mM - -
7r CTGGGCTGGGGACTCACCATTGTT
8 a 8f TCACTCCGCTCTCTCCTCTGCAGC 166 58 C, 1.5 mM - -
8r2 GACCCCCAGCAGAATGTAGAGCTT
8b 8f2 AAGCTCTACATTCTGCTGGGGGTC 173 58 C, 1.5 mM - -
8r TTCATCCTCCTCGGACCTCACTGCTCT
8 8f TCACTCCGCTCTCTCCTCTGCAGC 315 62 C, 1 mM 63 55
8r TTCATCCTCCTCGGACCTCACTGCTCT
Table 3: Mutations in UNC93A in tumours
ALLELE LOSS
TUMOUR AGE STAGE HISTOLOGY DIFF. 149 297 193 264 EXON MUTATION NORMAL
32 62 III endometrioid poorly NI NI NI NI 3 c.452G>A, W151X* Identical to the tumour
68 54 II mucious well - NI - - 3 c.452G>A, W151X * Identical to the tumour
60 75 III undifferentiated poorly NI + + - 3 c.452G>A, W151X * Identical to the tumour
50 47 I serious moderately NI - - - 3 c.452G>A, W151X * Identical to the tumour
30 52 I clear cell moderately - NI NI + 3 c.452G>A, W151X * Normal
28 49 III clear cell moderately - - NI - 4 c.625+1G>C * Identical to the tumour
39 53 II endometrioid poorly - + + - 4 c.625+1G>C * Identical to the tumour
43 72 III serious moderately - - + - 5 c.676C>T, R226X Normal
$, indicates the first base downstream of the splice donor site of exon 4. Diff.= differentiation; NI, not informative or unable to amplify; -, both alle-
les retained; +, LOH (loss of heterozygosity). Data as previously published [16]. All mutations are homozygous except when indicated by *. Normal 
refers to matched DNA from peripheral blood. The location of each mutation in the cDNA sequence is based on numbering from the inititiator 
codon ATG.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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Figure 8
Sequence traces of variants in exon 8 of UNC93A. A) Sequence trace of the nucleotide variant c.1159T>C in tumour
sample T19, matched normal DNA N19 and placental DNA. B) Sequence trace of the nucleotide variant
c.1208T>C+1209G>A in tumour sample T49, matched normal DNA N49 and placental DNA. C) Sequence traces of the
nucleotide variant c.1225G>A, in tumour sample T19, matched normal DNA N19 and placental DNA. D) Sequence variant
c.1334T>C+1335C>G in tumor sample T54, matched normal N54 and placenta. Corresponding amino acids are shown at the
top of each sequence trace.
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mapped within the interval of allele loss between D6S149
and D6S264. We have published the results of analysis of
other candidate genes within this interval separately [27].
In C. elegans, unc-93 is one of a set of five interacting genes
(unc-93, sup-9, sup-10, sup-11 and sup-18) involved in the
regulation or co-ordination of muscle contraction [30–
32]. Mutation of this gene gives a characteristic "rubber-
band" phenotype in the worm [28]. When a rubber band
mutant is touched on its head, the worm contracts and
then quickly relaxes without moving backwards, whereas
a wild-type worm simply moves backwards. Thus, the reg-
ulation or co-ordination is defective in the rubber band
mutants, although they can contract their body wall mus-
cles. These mutants are sluggish, flaccid, and defective in
egg laying. Mutations are quite diverse but the major ones
are e1500 which alters G388R in a membrane spanning
domain, the n200 animals have two mutations, A49V and
G562V which are in the hinge domains and in the n234
animals the Trp at position 534 is altered to a stop codon
[28]. It has been proposed that these mutations produce
aberrant proteins which are toxic and cause defects in the
regulation of muscle contraction. Interestingly, loss of
function, or null, mutations in unc-93 confers no visibly
abnormal phenotype. It has been concluded that this is
because the set of five genes involved in muscle contrac-
tion are functionally redundant of each other [28]. The
putative unc-93 proteins have two distinct regions: the N-
terminal is extremely hydrophilic, while the rest of the
protein has multiple potential membrane-spanning do-
mains. The expression of unc-93 in C.elegans is quite low
compared to other unc genes. It is suggested that unc-93 is
likely to encode a membrane-associated muscle protein in
C. elegans [28].
As none of the available ESTs for UNC93A encoded full
length cDNA, the entire coding sequence was amplified
by RT-PCR and sequenced completely. The amino acid se-
quence suggests that following a short leader peptide
there are at least seven membrane spanning domains sim-
ilar to that of unc-93. Comparison of the cDNA sequence
with that of the genomic sequence showed that the gene
encodes 8 exons as predicted by the exon prediction pro-
grammes. The data form RT-PCR, confirmed by sequenc-
ing suggests that there are two splice variants expressed
naturally. The second splice variant does not contain exon
4. UNC93A was expressed as two transcripts, 2.1 kb and
1.1 kb on Northern analysis. There is relatively less expres-
sion of the smaller transcript in the ovary compared to tes-
tis and small intestine. Importantly, none of the ovarian
cancer cell lines expressed UNC93A on northern analysis
although by more sensitive RT-PCR we did find expres-
sion in cell lines. Upon transfection of the GFP tagged
UNC93A, there is clear fluorescence at the membrane,
Table 4: Mutations in exon 8 in UNC93A in tumours
ALLELE LOSS
TUMOR AGE STAGE HISTOLOGY DIFF 149 297 193 264 MUTATION NORMAL
19 59 III Serous poorly NI NI + MI c.1159T>C, Y387H* c.1159T>C, Y387H*
c.1208T>C, M403T c.1208T>C, M403T
c.1225G>A, V409I*
c.1334T>C+1335C>G, V445A* c.1334T>C+1335C>G, V445A*
34 74 III Serous mod-
erately
+ + NI NI c.1159T>C, Y387H * Identical to the tumour
c.1208T>C, M403T
c.1334T>C+1335C>G, V445A*
44 58 III Serous poorly NI NI - - c.1159T>C, Y387H * Identical to the tumour
c.1208T>C, M403T
c.1225G>A, V409I *
c.1334T>C+1335C>G, V445A*
49 44 Ic Serous mod-
erately
- NI - - c.1159T>C, Y387H * Identical to the tumour
c.1208T>C, M403T
c.1208T>C+1209G>A*, M403T,
c.1334T>C+1335C>G, V445A*
54 28 Ia Mucinous well NI NI NI - c.1159T>C, Y387H * Identical to the tumour
c.1208T>C, M403T
c.1334T>C+1335C>G, V445A*
NI, not informative or unable to amplify; -, both alleles retained; +, LOH (loss of heterozygosity); MI, microsatellite instability. Data as previously 
published [16]. All mutations are homozygous except when indicated by *. Normal refers to matched DNA from peripheral blood.The location of 
each mutation in the cDNA sequence is based on numbering from the inititiator codon ATG.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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confirming that it is a membrane associated protein. It is
now apparent there are homologous unc-93 genes in Dro-
sophila and a second unc-93 gene in C.elegans. There is
quite significant similarity among the species, in particu-
lar in the membrane spanning domains.
To evaluate if this gene is involved in the pathogenesis of
sporadic ovarian cancer, mutation detection analysis was
carried out on a panel of 36 malignant tumours using
methods such as SSCP (both 32P-labelled and fluorescent
dye-labelled primers) and DHPLC. In general, there was
good concordance between conventional SSCP and F-SS-
CP. However, DHPLC did detect the mutations in exons 5
and 1 which were not identified by SSCP. The use of both
methods significantly increased the success of identifying
mutations. Overall, 18/36 tumours were identified to
have mutations that might have functional significance
(Fig. 11). Both missense and nonsense mutations were
identified. However, surprisingly the majority of these
mutations were present in the matched normal DNA for
each individual tumour. Only in three tumours (8%) were
specific mutations identified. Firstly, in exon 3 in T30,
c.452G>A which alters residue Trp to a stop codon. Sec-
ondly, in exon 5 in T43, c.676C>T which alters Arg to a
stop codon. Both the above mutations should alter the
reading frame and truncate the protein. Thirdly, one mis-
sense mutation in T19 in exon 8, c.1225G>A which alters
Val to Ile. Direct sequencing revealed that many of the mu-
tations identified in the tumours were also present in the
cell lines. However, there was one missense mutation
c.874G>A in exon 5 identified (Ala-Val) only in UCI101
and a frequent mutation in exon 6, c.874G>A (Val-Ile)
which were observed in 6/8 cell lines. The mutations iden-
tified in UNC93A were more numerous than that identi-
fied in unc-93 mutants in C.elegans and their location was
not identical. It is possible that the mutations in UNC93A
may be due to the presence of a pseudogene. Analysis of
UNC93A sequence in the database has not identified a
pseudogene or any other related genes. Secondly, South-
ern analysis of normal genomic DNA confirmed that
UNC93A is a single copy gene (data not shown).
Table 5: Mutations in UNC93A in ovarian cancer cell lines
CELL LINE EXON 1 EXON 3 EXON 4 EXON 5 EXON 6 EXON 8
41M - - - - c.874G>A, V292I * c.1159T>C, Y387H *
c.1208T>C, M403T
c.1208T>C+1209G>A*, M403T,
c.1334T>C+1335C>G, V445A*
59M c.1-32T>Ga - - - c.874G>A, V292I * c.1159T>C, Y387H *
c.1208T>C, M403T *
c.1334T>C+1335C>G, V445A*
OAW28 - - - - c.874G>A, V292I * c.1159T>C, Y387H *
c.1208T>C, M403T
c.1334T>C+1335C>G, V445A*
c.1159T>C, Y387H *
OAW42 c.1-32T>G c.452G>A, W151X * c.500-15T>Gb - c.874G>A, V292I * c.1208T>C, M403T
c.1208T>C+1209G>A*, M403T,
c.1334T>C+1335C>G, V445A*
PEO1 c.1-32T>G c.452G>A, W151X - - - c.1159T>C, Y387H *
c.1208T>C, M403T
c.1208T>C+1209G>A*, M403T,
c.1334T>C+1335C>G, V445A*
- c.1159T>C, Y387H *
PEO4 c.1-32T>G c c.452G>A, W151X - - c.1208T>C, M403T
c.1208T>C+1209G>A*, M403T,
c.1334T>C+1335C>G, V445A*
SKOV3 c.1-32T>G c.452G>A, 
W151X*
- - c.874G>A, V292I c.1159T>C, Y387H *
c.1334T>C+1335C>G, V445A*
UCI-101 c.1-32T>G - - c.659C>T
A220V*
c.874G>A, V292I
c.1159T>C, Y387H *
c.1208T>C+1209G>A*, M403T,
c.1334T>C+1335C>G, V445A*
a: 32 bases upstream of the 'ATG' site. b: 15 bases upstream of start of exon4. All mutations are homozygous except when indicated by an *. The 
location of each mutation in the cDNA sequence is based on numbering from the inititiator codon ATG.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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The identification of the mutation W151X in exon 3 in 4
matched normal DNA samples as well as in tumours
(11%), suggested that this might be present in the normal
population. The frequency of this polymorphism in the
normal population was 3/50 (6%). This included at least
one sample having a homozygous mutation. In exon 5,
the mutation c.676C>T, which also creates a stop codon,
was identified in one tumour (<3%). Screening of 50 nor-
mal DNA samples identified this sequence change in one
sample (2%). The identification of these two mutations in
the normal population suggest that these represent low
frequency polymorphisms. Such polymorphisms are rare
and an extensive search of the literature identified one re-
port involving BRCA2 where a stop codon polymorphism
was found in one patient [33]. However, recently genome
wide scanning for SNPs in coding sequences have identi-
fied a low frequency of such mutations in less than 1%
[34,35] of the genes analysed. The functional impact of
these rare mutations are at present unknown. It is estimat-
ed that on average the number of polymorphic sites per
kilobase of DNA was 3.4 in the coding region and 50% of
them coded for an aminoacid change [35]. In the coding
sequence of UNC93A, the frequency is much higher (6.4/
kb). Only genes of the HLA complex and the P450 cyto-
chrome enzymes have higher rates of polymorphism than
this.
Conclusions
The frequency and nature of the mutations in UNC93A in
ovarian tumours and cell lines suggests the following.
Firstly, UNC93A is an unusual gene which is highly poly-
morphic and the truncating mutations may not result in
any deleterious function in the normal population. This
might be due to compensation by other related genes yet
to be identified. Secondly, because of identification of sig-
nificant mutations in the germline of these patients, it is
probable that these mutations predispose to ovarian can-
cer. Polymorphic variants of genes in individuals may in-
crease the risk of a particular cancer. Extensive research is
being performed to identify such genes which might ex-
Figure 9
c.452G>A mutation in exon 3 in normal DNA. A) Electrogram of F-SSCP of exon 3 from DNA from placenta and two
normal controls ORK67 and ORK97 are shown. Abnormal peaks are indicated by arrows. B) Sequence trace showing the
mutation c.452G>A in exon 3 with homozygous (ORK97) and heterozygous (ORK 67) alteration compared to placenta.
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plain polygenic diseases. Although several candidate
genes have been evaluated for such association in ovarian
cancer, none have been identified that could significantly
increase the risk of ovarian cancer. Further research is re-
quired to discover the allele frequency of the sequence
variants in the coding sequence of UNC93A in the normal
population and their possible association with ovarian
cancer. However, the results presented in this paper do
not suggest that UNC93A is the tumour suppressor gene
to explain the allele loss observed between D6S264 and
D6S149 in ovarian tumours.
Methods
Tumour tissues and blood samples
Fresh tissues (tumours, normal ovary and placenta) and
peripheral blood samples were collected from patients in
John Radcliffe and Churchill Hospitals, Oxford. Tissue
samples were collected at surgery and stored in liquid ni-
trogen. Blood samples were collected in sodium chloride-
EDTA tubes and processed for DNA extraction. Formalin
fixed paraffin embedded tumour samples and matched
normal tissues were obtained from pathology archives.
Primers
All the primers, including the fluorescent labelled (HEX,
FAM) primers were synthesised by the Oligonucleotide
synthesis laboratory, Clare Hall, ICRF.
Cell lines
Eight ovarian cancer cell lines [36,37] and the 293-T cell
line were supplied byCell Services, Clare Hall, ICRF. The
cells were cultured in media and 10% fetal calf serum and
maintained in 5% CO2 at 37C.
DNA extraction
DNA was extracted from tumours and cell lines following
standard protocols. Sections from paraffin blocks were
mixed with 100% Xylene (1 ml/4–5 paraffin sections).
The mixture was incubated at room temperature for 30
min to 1 hr and spun at 10, 000 g for 3 to 5 min. The su-
pernatant was discarded and the precipitate was washed
twice, air dried and digested in buffer (50 mM Tris-HCl,
pH 8.0; 25 mM EDTA, 1% Tween 20, with freshly added
200 g/ml proteinase K) at 37C overnight followed by
95C for 10 min to inactivate the proteinase K.The sam-
ples were then spun for 1 min at 10,000 g and the super-
natant was used for PCR. DNA from dried polyacrylamide
gel was obtained by soaking the band cut from the gel in
50–100 l of dH2O overnight at 4C and the supernatant
Figure 10
c.676C>T mutation in normal DNA. Agarose gel showing restriction digest by Nde1 of exon 5 amplified by PCR from
normal DNA samples. The PCR product from ORK 29 shows an additional band of appropriate size suggesting heterozygous
alteration, c.676C>T.
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was used as template in PCR. DNA from blood samples
were extracted as previously described [16].
Northern analysis
The membrane was prehybridised in ExpressHyb™ Hy-
bridisation Solution (Clontech) at 68C for 1 hour.
UNC93A full length cDNA was labelled with 32P-dCTP
using Megaprime™ labelling systems (Amersham) and pu-
rified through G-50 Sephadex column. The membrane
was hybridised in ExpressionHyb™ Hybridisation Solu-
tion (Clontech) at 68C with recommended amount of
denatured probe overnight. Membranes were washed ac-
cording to manufacturer's instructions.
RT-PCR
Total cellular RNA was isolated from 5–10  107 cells of
each cell line with RNeasy Midi/Maxi kit (QIAGEN) ac-
cording to manufacturer's instructions. Total RNA from
normal ovary and placenta were extracted using RNAZol
B (Biogenesis) according to manufacturer's instructions. 2
g of RNA from each cell line was used in a RT-PCR reac-
tion using QIAGEN One Step RT-PCR Kit (QIAGEN) ac-
cording to manufacturer's instructions (forward primer
sequence in exon 3: TTTGATCCCCACCTCCATACTG; re-
verse primer sequence in exon 5: GGAGAGGAATCCTT-
GCTGCAATC). The reaction was performed on a PTC-200
(GRI Lab Care Service) for synthesis of first strand (50C,
40 min), initial PCR activation step (95C, 15 min), 40 cy-
cles of denaturation (94C, 40 sec), annealing (64C, 1
min), extension (72C, 1 min), and 1 cycle of final exten-
sion (72C, 10 min).
Mutation detection analysis
P32-SSCP
Individual exons were amplified from genomic DNA from
a panel of 10 malignant tumours, labelled with 32P-
dCTP, and resolved using Mutation Detection Enhance-
ment (MDE) gel (FMC Corporation). The PCR reactions
were paused at the 25th cycle, 10 l of each reaction was
taken out for evaluating the PCR product on an conven-
tional agarose gel, and 0.5 l -32P-dCTP together with
0.2 l Taq polymerase were added to each sample. The
PCR reaction was continued for a further 5 cycles. 1 l of
each -32P labelled PCR sample was mixed with 10 l of
sample loading buffer (95% formamide, 10 mM NaOH,
0.25% bromophenol blue and 0.25% xylene cyanol) on a
96-well plate (a standard SSCP gel can run 32 samples).
Samples were denatured at 95C for 3 min and immedi-
ately transferred to ice before loading 4 l of each sample
on to a 0.5  MDE gel with 10% glycerol. The MDE gel was
prepared according to manufacturer's instruction. The
samples were run at a constant power of 8–12 Watts for 12
to 16 hours at room temperature. The gel was dried for 2
hours at 68C and then exposed to X-ray film.
F-SSCP
Individual exons were amplified by PCR from genomic
DNA from a panel of 36 malignant tumours using primers
labelled with HEX (green, forward primers), and FAM
(blue, reverse primers) and applied to MDE gel on a ABI
377 system (PE Applied Biosystems). Standard PCR reac-
tions were carried out to amplify the individual exon in a
50 l reaction using these primers. One l of each fluores-
cence-dye labelled PCR sample was diluted (1:5 to 1:10).
One l of the diluted sample was combined with 3.0 l of
loading buffer (Deionized formamid, 0.5 l of GeneScan
size standard (TAMRA), 0.5 l of 100 mM NaOH, and 0.5
l of Blue dextran EDTA (50 mM EDTA, 50 mg/ml blue
dextran), denatured at 90C for three minutes and loaded
to the ABI 377 Sequencer. The gel (0.5% MDE and 10%
glycerol) was run at the settings for wattage-limiting mod-
ule (GS Run 60W C CHILLER) for 10–12 hours using filter
set C. The temperature of the gel was controlled at 19C by
a cooling system (Betta Tech). The data was collected by
ABI 377 software and analysed using the GeneScan 672
software (Version 3.1).
Figure 11
Mutations in UNC93A All the mutations observed in tumours or cell lines in individual exons are as indicated.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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DHPLC analysis
'Touchdown' PCR [29] was performed to amplify individ-
ual exons. Briefly, a 50 l PCR reaction contained 30 ng
genomic DNA, 10 pmol of each primer, 0.5 mM of dNTPs,
0.3 l of a combination of Amplitaq Gold (Perkin Elmer)
and Pfu Turbo (Stratagene) at 9:1 ratio, 5 l 10  Ampli-
Taq Gold buffer (Perkin Elmer), and 3 to 5 l of MgCl2
(25 mM) optimised for each primer set (Table 2). Ampli-
fication was carried out on a PTC-200 (GRI Lab Care Serv-
ice) without oil. PCR conditions were initial denaturation
step for one cycle (10 min at 95C); 14 cycles of denatur-
ation (30 sec at 95C), annealing (30 sec, at temperature
7.5C higher than the optimised annealing temperature
for each primer pair at the first cycle and subsequently de-
creased by 0.5C per cycle), and extension (30 sec at
72C); a further 20 cycles of denaturation (30 sec at
95C), annealing(30 sec at the optimal temperature
shown in Table 2), and extension (30 sec at 72C), and a
final extension of 1 cycle at 72C for 7 min. Touch-down
PCR products were subjected to DHPLC analysis accord-
ing to conditions (Table 2) on a WAVE Machine (Transg-
enomic, Omaha, USA). Standard buffer mixtures were
used, as recommended by Transgenomic: buffer A, 0.1 M
triethylammonium acetate (TEAA), pH 7.0; buffer B, 0.1
M TEAA, pH 7.0 + 25% acetonitrile. Gradients were de-
signed to increase the percentage of buffer B at a rate of
2%/minute for four minutes. Since DHPLC detects mis-
matches between DNA sequences, not actual mutations,
we consequently analysed PCR products from tumour
DNA alone as well as tumour DNA mixed 1:1 with normal
DNA from an individual of known sequence. This was pe-
formed by denaturation at 95C for 4 minutes, followed
by 42 cycles of decreasing temperature at 1.6C per cycle
for 1 minute until 4C.
Automated DNA sequencing
PCR products were purified with QIAquick PCR Purifica-
tion kit (QIAGEN) and sequenced with BigDye Termina-
tor Cycle Sequencing Ready Reaction kit (Perkin Elmer)
on an Applied Biosystems model 377 DNA Sequencer (PE
Applied Biosystems) according to manufacturer's instruc-
tion. Sequencing to confirm any variation from normal
sequence was performed twice.
Construction of pEGFP-UNC93A and fluorescence
The entire coding region of UNC93A was amplified by RT-
PCR with 1 g of total RNA from cell line OAW28 using
QIAGEN One Step RT-PCR Kit (QIAGEN) according to
manufacturer's instructions (forward primer sequence:
CTTTTCATCCAGCACAATGG; reverse primer sequence:
TTCATCCTCTGCCTGGTTG; the annealing temperature
was 60C) and was subcloned into pGEM-T-Easy Vector
(Promega). The cDNA of UNC93A was then released by
digestion with HindIII and EcoRI, and subcloned into
pEGFP-N3 mammalian expression vector in frame with
the fluorescent EGFP coding region at its C-terminal end.
To visualise the expression and location of the EGFP-
UNC93A fusion protein in the 293-T cells transfected by
this construct, transfected cells were transferred to sterile
cover slips 24 hours after the transfection. After a further
culture of 24 hours, the cells were fixed with PBS/4% para-
formaldehyde and visualised under a fluorescent micro-
scope according to manufacturer's instructions.
Immunoprecipitation and immunoblotting
293-T cells were transfected with the EGFP-UNC93A con-
struct, and EGFP vector respectively with Effectene (QIA-
GEN). After incubation for 48 hours at 37C, transfected
cells were lysed by adding 1.0 ml lysis buffer (1% Nonin-
det P 40, 50 mM Tris (PH 7.5), 150 mM NaCl, 10 mM ED-
TA.) containing freshly added protease inhibitors (1 g
each of Leupeptin and Pepstin per ml, 10 g each of Apro-
tinin and Trypsin per ml, and 0.5 mM of Phenylmethyl-
sulfonyl Fluoride per ml) at 0C for 30 minutes. The lysate
was clarified by centrifugation for 30 min at 16,000 g at
4C. The supernatant was incubated with monoclonal
GFP antibody (1:500 dilution) at 4C for 3 hours and
then with 25 l of protein A-agarose beads at 4C for two
hours. The immune complexes were washed twice in ice-
cold cell lysis buffer supplemented with 0.5 M NaCl, and
twice in ice-cold cell lysis buffer and denatured by boiling
for 5 min in 2  SDS sample sample buffer (50 mM Tris-
HCl, PH 6.8, 2% SDS, 10% glycerol, 5% -mercaptoetha-
nol, 0.25% bromophenol blue). The immune complexes
were resolved by 10% SDS polyacrylamide gel electro-
phoresis (PAGE) and then transferred to Hypond-P nitro-
cellulose membrane (Amersham). The membrane was
blocked overnight in PBSA (5% non-fat milk, 0.1% Tween
20) at 4C, rinsed with PBSA (0.1% Tween 20), and then
incubated with monoclonal GFP antibody (1:3000 dilu-
tion) for 1 hour in PBSA (0.5% non-fat milk, 0.1% Tween
20), rinsed with PBSA (0.1% Tween 20), and incubate
with anti-Mouse Horse-Radish-Peroxidase (1:5000 dilu-
tion, Clontech) for 1 hour in PBSA (0.5% non-fat milk,
0.1% Tween 20). The membrane was then washed with
PBSA (0.5% non-fat milk, 0.1% Tween 20) for 50 min at
room temperature with several changes of the wash solu-
tion. Bound proteins were detected by chemilumines-
cence (Amersham).
Accession numbers
The accession number of sequence for RP3-366N23:
AL021331, RP3-431P23:AL009178. RP11-178P20:
AL592444. The approved symbol for the human homo-
logue of unc-93 is UNC93A and the accession number is
AJ508812.BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/20
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